Digital Transformation Opportunities Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTOC research report →
Price Chart
About the company
Digital Transformation Opportunities Corp. functions as a blank check company, specifically created to complete a business combination. This may involve a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transactions with one or more target enterprises.
- CEO
- Kevin Nazemi
- IPO
- 2021
- HQ
- Bellevue, WA, US
Get TickerSpark's AI analysis on DTOC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $262.55M
- P/E
- -16.12
- PEG
- 0.24
- P/S
- 0.18
- P/B
- 8.13
- EV/EBITDA
- 225.76
- Div Yield
- 0.00%
- Gross Margin
- 6.70%
- Op Margin
- -0.99%
- Net Margin
- -0.23%
- ROE
- 5.56%
- ROIC
- -6.56%
Latest fiscal year · YoY change
- Revenue
- $1.76B+0.0%
- Gross Profit
- $117.85M+0.0%
- Op Income
- $-17,429,000
- Net Income
- $-9,523,000+0.0%
- EPS
- $-0.69+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $39.60
- 52W Low
- $7.02
- 50D MA
- $11.25
- 200D MA
- $10.46
- Beta
- 0.03
- RSI (14)
- 66
- Avg Volume
- 120.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
American Oncology Network posted 20% revenue growth in Q1 2024, but higher drug and supply costs kept profitability under pressure as it continued expanding its platform and acquisitions.· May 16, 2024
- Revenue rose to $364.3 million, up 20% year over year, driven by a 12.8% increase in revenue per encounter and 6.2% more patient encounters.
- Cost of revenue climbed to $354.9 million, with management citing higher drug and medical supply costs plus mix and volume effects.
- Net loss before non-controlling interest widened to $24.9 million from $1.5 million a year ago; adjusted EBITDA was $2 million versus $4 million.
- AON completed two practice acquisitions in Q1 and announced two more in Q2, while adding 17 providers in the quarter and 40 year to date.
- Management highlighted new initiatives including MiBA and NOVA, positioning them as ways to enhance ancillary services and personalized care.
Revenue was $364.3 million in Q1 2024 versus $303.7 million a year ago, an increase of $60.6 million or 20%. Revenue per encounter increased 12.8%, and patient encounters increased 6.2%, contributing $59.7 million and $18.7 million, respectively, to the revenue increase. Cost of revenue was $354.9 million versus $278.5 million, with drug and medical supply costs, higher cost per encounter, and volume growth cited as drivers; cost of revenue also included $13.3 million of equity-based compensation. Net loss before non-controlling interest was $24.9 million versus $1.5 million in the prior-year quarter, and adjusted EBITDA was $2 million versus $4 million. The company ended the quarter with total liquidity of $132.7 million, including $74.9 million of cash and cash equivalents and $30.1 million of short-term marketable securities. No explicit next-quarter or full-year financial guidance was given on the call.
Todd Schonherz emphasized that momentum from the prior year continued into 2024 and framed the quarter around execution of AON’s growth plan. He pointed to completed and announced acquisitions, provider additions, and expansion in existing and new markets as evidence that the platform is attracting practices. His tone was upbeat and strategic, with repeated emphasis on AON’s integrated care model, technology platform, and role as a national community oncology destination.
David Gould focused on the quarter’s financial bridge: revenue growth was strong at 20%, but costs rose even faster, pushing cost of revenue to $354.9 million and leaving net loss before non-controlling interest at $24.9 million. He cited $13.3 million of equity-based compensation within cost of revenue and noted liquidity of $132.7 million, including $74.9 million in cash and equivalents, $30.1 million in short-term marketable securities, $26.7 million of incremental borrowing capacity under the PNC loan facility, and $1 million under the PNC line of credit. He also said $81.3 million was outstanding on the PNC loan facility at 7.1%, while the line of credit was undrawn.
There was no substantive analyst Q&A in the transcript provided, so no new concerns or management responses were disclosed beyond the prepared remarks. The only additional commentary was Todd’s closing emphasis that AON remains focused on improving efficiencies, investing in its platform, and updating investors on second-quarter results next quarter.
The bull case is that AON is still growing quickly, with 20% revenue growth, expanding patient volume, and higher revenue per encounter all moving in the right direction. Management also described a strong acquisition pipeline, new market expansion, and new technology offerings like MiBA and NOVA that could deepen the platform and support ancillary services.
The main bear case is margin pressure: cost of revenue rose sharply and exceeded quarterly revenue, while net loss widened materially and adjusted EBITDA declined year over year. The call also did not include formal financial guidance, and the business appears sensitive to drug and supply costs, mix, and leverage, with $81.3 million outstanding on the PNC facility at 7.1%.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 18.3%
- Shares Outstanding
- 10.11M
- Float Shares
- 1.85M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Spring Creek Capital LLC | 160.00K | 0 |
| Pinz Capital Management, LP | 49.58K | ▼ 857 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 24 | Divers Stephen | other | 3,369 |
| Jan 3, 24 | Divers Stephen | other | 9,893 |
| Sep 20, 23 | Digital Transformation Sponsor LLC | other | 5,273,125 |
| Sep 25, 23 | Saba Capital Management, L.P. | sell | 205,512 |
| Sep 20, 23 | AEA GROWTH EQUITY FUND LP | other | 4,831,463 |
| Sep 20, 23 | AEA GROWTH EQUITY FUND LP | other | 1,820,147 |
| Sep 20, 23 | AEA GROWTH EQUITY FUND LP | other | 0 |
| Sep 20, 23 | Digital Transformation Sponsor LLC | other | 8,112,500 |
| Sep 20, 23 | Digital Transformation Sponsor LLC | other | 6,113,333 |
| Sep 20, 23 | Fluegel Bradley M | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DTOC coverage
Recent articles, reports, and earnings notes.
No research on DTOC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DTOC report →Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer
globenewswire.com · Apr 30
American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, to go Public through Business Combination with Digital Transformation Opportunities Corp.
businesswire.com · Oct 6
Digital Transformation Opportunities Corp. Announces the Separate Trading of Its Class a Common Stock and Warrants, Commencing on April 30, 2021
businesswire.com · Apr 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.